Search
Close this search box.

Day: December 4, 2023

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) —  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the […]

Read More »

Zenas BioPharma Fortalece a Liderança Executiva com a Nomeação de Jennifer Fox como Diretora de Negócios e Financeira, e de Tanya Fischer, MD, Ph.D. como Dirigente de P&D e Médica

Com a expansão dessa liderança estratégica e operacional, a Zenas se posiciona para o crescimento esperado com o avanço do voltadas para inflamações e imunologia nos ensaios clínicos em estágio avançado de várias indicações potenciais de I&I WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se […]

Read More »

Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer

Le renforcement du leadership stratégique et opérationnel permet à Zenas de se développer et les essais cliniques en phase avancée sur l’obéxélimab progressent, pour de multiples indications potentielles dans l’I&I WALTHAM, Massachusetts, 04 déc. 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à devenir un leader dans le développement et la commercialisation […]

Read More »

Recent Posts

Advertisement